Charles River Laboratories International (NYSE:CRL) Updates FY25 Earnings Guidance

Charles River Laboratories International (NYSE:CRL) issued an update on its FY25 earnings guidance on Wednesday morning. The company provided EPS guidance of $9.10-$9.60 for the period, compared to the consensus EPS estimate of $9.60. The company issued revenue guidance of $3.77-$3.87 billion, compared to the consensus revenue estimate of $3.87 billion. Charles River Laboratories International also updated its FY 2025 guidance to 9.100-9.600 EPS.

Charles River Laboratories International Stock Performance

Shares of NYSE:CRL traded up $0.09 during trading on Friday, hitting $162.34. 180,010 shares of the company traded hands, compared to its average volume of 1,027,646. The business’s fifty day moving average is $173.39 and its 200-day moving average is $188.81. Charles River Laboratories International has a one year low of $150.79 and a one year high of $275.00. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $8.30 billion, a price-to-earnings ratio of 1,082.29, a PEG ratio of 6.77 and a beta of 1.37.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International’s revenue was down 1.1% on a year-over-year basis. During the same period in the prior year, the business posted $2.46 EPS. As a group, equities analysts predict that Charles River Laboratories International will post 9.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Robert W. Baird decreased their target price on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a research report on Thursday. CLSA lowered shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target on the stock. in a report on Monday, November 18th. Bank of America dropped their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. Morgan Stanley decreased their target price on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 5th. Finally, The Goldman Sachs Group dropped their price target on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. Three analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $195.71.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).